首页 | 官方网站   微博 | 高级检索  
     

叶酸偶联纳米紫杉醇脂质体在大鼠体内的药物代谢动力学研究
引用本文:李娜,陈卫,李红霞.叶酸偶联纳米紫杉醇脂质体在大鼠体内的药物代谢动力学研究[J].中国妇产科临床杂志,2014(2):148-152.
作者姓名:李娜  陈卫  李红霞
作者单位:北京大学第九临床医学院(首都医科大学附属北京世纪坛医院),100038
基金项目:北京市科委项目(Z080507030808028)
摘    要:目的探讨叶酸偶联纳米紫杉醇脂质体在大鼠体内的药物代谢动力学。方法将SD大鼠尾静脉注射叶酸偶联纳米紫杉醇脂质体(实验组)及普通紫杉醇脂质体(对照组),采用高效液相色谱分析紫外(HPLC—UV)法检测两组大鼠体内血药浓度经时变化,Excel绘制药物经时曲线。药物代谢统计分析软件(DAS)模拟房室模型并计算药代动力学参数。结果①紫杉醇标准品血样在0.07-30μg/ml浓度时呈良好的线性关系,浓度测定的日内、日间精密度的相对标准偏差(RSD)值〈6%,高(10.0μg/ml)、中(2.0μg/ml)、低(0.2μg/ml)浓度下的紫杉醇标准品血样的提取回收率均〉90%;②实验组血药浓度经时曲线符合1/C权重的三室模型,对照组符合1/C2权重的二室模型;③实验组药物快、慢分布相半衰期分别是(0.12±0.10)h和(0.40±0.08)h,消除半衰期是(3.29±1.02)h,血浆清除率(CL)是(1.37±0.04)L/(kg·h),0~t时血药浓度一时间曲线下面积(AUC)及AUC(0~∞)分别是(12.19±0.40)mg/(L·h)和(14.61±0.40)mg/(L·h);对照组药物分布相半衰期是(0.09±0.08)h,消除半衰期是(2.57±0.51)h,CL是(1.50±0.10)L/(kg·h),AUC(0~t)及AUC(0~∞)分别是(9.30±0.48)mg/(L·h)和(13.39±0.92)mg/(L·h);两组消除半衰期、CL、AUC(0-t)和AUC(0~∞)比较,差异均有统计学意义(P〈0.05)。结论叶酸偶联纳米紫杉醇脂质体与普通紫杉醇脂质体均能较快地分布于体内并达到平衡,但是前者半衰期较长,清除速度略快,生物利用度高。

关 键 词:叶酸偶联纳米紫杉醇脂质体  紫杉醇脂质体  药物代谢动力学  高效液相色谱紫外检测法

Study on pharmacokinetics of folic acid coupling nanometer paclitaxel liposome in rats
Affiliation:LI Na, CHEN Wei, LI Hongzcia (Department of Gynecology and Obstertrics , Affiliated Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, China)
Abstract:Objective To study the pharmacokinetics o{ folie acid coupling nanometer paclitaxel liposome in rats. Methods Rat's plasma was extracted, preprocessed and then analysed after paclitaxel liposome and folic acid coupling nanometer paclitaxel liposome was injected. HPLC- UV was used to determine the plasma drug level in rats, and excel software was used in drawing the plasma concerntration- time curves, drug and statistics (DAS) software in calculation of compartment model and pharmacokinetics parameters. Results (J) Linearity was con- firmed over the whole calibration range from 0.07 ~g/ml to 30/lg/ml (r=0. 9998). The intra- and inter- day pre- cisions (RSD) of analysis were lower than 60/00. The extraction recovery at three different concentration (10.0, 2.0, 0.2/~g/ml) was better than 90~/oo. (~) The concentration-time profile for folio acid coupling nanometer paclitaxel liposome injection could be best described by three - compartment model fitted by 1/C2 weight and paclitaxel liposome injection was described by two- compartment model fitted by 1/C2 weight. (3) T1/2α, T1/2β of folic acid coupling nanometer paclitaxel liposome were (0.12±0.10) h and (0.40±0.08) h, t1/27 was (3.29±1.02) h, CL was (1.37±0.04) L/(kg·h), AUC (0-t) , AUC (0-∞) were (12.19±0.40) mg/(L·h) and (14.61± 0.40) mg/ (L·h), while T1/2α of paclitaxel liposome was (0.09±0.08) h, T1/2α was (2.57±0.51) h, CL was (1.50±0.10) L/(kg · h), AUC (0-t) and AUC (0-∞) were (9.30±0.48) mg/(L·h), (13.39!0. 92) mg/(L · h). (4) The t-test results show that the elimination half- life time, CL, AUC (Out), AUC (0-∞) were all statistically significant. Conclusion Folic acid coupling nanometer paclitaxel liposome can be distributed in the whole body and achieve balance fast, last for a longer time, and have higher bioavailability.
Keywords:folic acid coupling nanometer paclitaxel liposome  paelitaxel liposome  pharmacokinetics  high- performance liquid chromatography- ultraviolet
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号